The information in
this alert provides an update to SDA/2020/012 issued on 21st August
2020.
Essential Pharma
has informed the Department of Health and Social Care (DHSC) of its decision to
reverse the discontinuation of Priadel 200mg and 400mg tablets from the UK
market with immediate effect, whilst facilitating pricing discussions. As such
the discontinuation notice issued to DHSC earlier this year has been withdrawn.
In light of this,
clinicians across all healthcare settings are advised that there is no longer a
need to implement system wide switching of patients from Priadel tablets to an
alternative lithium carbonate preparation until further notice.
All Patients who require lithium treatment
should now continue to be managed in line with usual clinical practice
underpinned by the relevant NICE guidance.
Although DHSC cannot confirm a discontinuation will not take
place in future, it is important to note that under the Health Service Products
(Provision and Disclosure of Information) Regulations 2018, marketing
authorisation holders must provide the DHSC a minimum of six months’ notice of
an intention to discontinue a product from the UK market.